ImmunityBio, Inc. IBRX
6.67 USD -0.08 (-1.11%)
At closeNov 11, 2026, 7:48 PM EST
6.63 -0.04 -0.60%
After hours · Nov 11, 7:48 PM ET
6.51 Day range 6.85
1.95 52-week range 12.43
- YTD
- +236.87%
- 1 year
- +211.68%
News
businesswire.com New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and…
businesswire.com ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming…
zacks.com IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18% ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.
fool.com Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy? ImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate. Even after Monday's drop, the stock trades at roughly 39…
benzinga.com ImmunityBio Reports Wider Quarterly Loss ImmunityBio Inc. (NASDAQ:IBRX) stock is trading lower on Monday after the company's third-quarter earnings missed expectations.
benzinga.com ImmunityBio Reports Wider Quarterly Loss ImmunityBio stock falls as Q3 revenue misses estimates, despite positive ANKTIVA bladder cancer trial results and Israeli approval.
zacks.com ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
benzinga.com ImmunityBio Q3 Adj. EPS $(0.09) Misses $(0.08) Estimate, Sales $48.841M Miss $59.250M Estimate ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 28.57 percent decrease over losses of…
benzinga.com ImmunityBio Reports Expanded ANKTIVA Approval And Global Market Expansion Across 35 Countries Label Expansion and Global ProgressFDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved our supplemental Biologics License Application (sBLA) expanding the…
businesswire.com ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial…
benzinga.com ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors Partnership brings first-in-class IL-15 receptor agonist immunotherapy to patients in IsraelIsraeli Ministry of Health grants approval for ANKTIVA® (nogapendekin alfa inbakicept) in combination with…
businesswire.com ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ JERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health…- benzinga.com ImmunityBio Says ANKTIVA Plus BCG Meets Primary Endpoint In Phase 3 NMIBC Trial, Supports Planned FDA Filing ANKTIVA® plus BCG met the primary efficacy endpoint in the randomized registrational trial of 370 subjects comparing intravesical ANKTIVA plus BCG with BCG alone; additional study details will be…
businesswire.com ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in…
benzinga.com ImmunityBio Treats First Patient In Europe With ANKTIVA In Combination With Bacillus Calmette-Guérin ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin alfa inbakicept) in…
businesswire.com ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with…
benzinga.com Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original Jim Cramer called ImmunityBio a strong speculative buy, favored Monster over Celsius, avoided USA Rare Earth and liked Glacier Bancorp.
defenseworld.net ImmunityBio, Inc. $IBRX Stake Trimmed by Davidson Kahn Capital Management LLC Davidson Kahn Capital Management LLC lessened its stake in ImmunityBio, Inc. (NASDAQ: IBRX) by 50.9% during the third quarter, according to its most recent filing with the Securities and Exchange…- benzinga.com ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle…
benzinga.com ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle…
businesswire.com ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its…
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment A recent study published in the Journal of Urology revealed promising long-term results for ImmunityBio, Inc. (NASDAQ:IBRX) and its immunotherapy treatment, ANKTIVA.
benzinga.com ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.
benzinga.com ImmunityBio Announces Data From Its Phase 2/3 QUILT-3.032 Trial Of ANKTIVA In Combination With Bacillus Calmette-Guerin Demonstrates 71% Complete Response Rate In Participants With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The…
businesswire.com ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032…
zacks.com FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer IBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.
benzinga.com Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14 Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $12 to $14.
benzinga.com ImmunityBio Stock Climbs Thursday: What's Going On? ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Thursday after the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive…
benzinga.com ImmunityBio Stock Climbs Thursday: What's Going On? ImmunityBio shares are trading higher Thursday after the FDA approved expansion for its bladder cancer therapy ANKTIVA.- benzinga.com HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
businesswire.com FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the…
benzinga.com Why Is ImmunityBio Stock Gaining Wednesday? ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
defenseworld.net ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
gurufocus.com ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Ch
businesswire.com ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and…
benzinga.com ImmunityBio Stock Jumps: What's Going On? ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10)…
benzinga.com ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding treatment options for NMIBC and NSCLC.
benzinga.com Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory Patients The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to…
benzinga.com Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now.
benzinga.com Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation' Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun concept, also likes Trulieve Cannabis (TRLV) and advised holding onto Ashland (ASH).- benzinga.com HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
- benzinga.com ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung Cancer ImmunityBio, Inc. ((
- benzinga.com ImmunityBio Announces Preliminary Results From News Economic Analysis Showing That Anktiva Plus Bacillus Calmette–Guérin Achieved A Lower Cost Per Sustained Complete Responder ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced preliminary results from a new health economic analysis demonstrating that ANKTIVA® (nogapendekin alfa…
benzinga.com ImmunityBio Announces New Survey Data Showing Diverse Treatment Preferences And Priorities Of Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia,…
benzinga.com TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.